Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5695104 | 1.00 | CA2 (0.40) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL5367628 | 1.00 | CA2 (0.40) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL10305250 | 1.00 | CA2 (0.40) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL7154436 | 0.88 | CA2 (0.37) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL7148630 | 0.88 | CA2 (0.37) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL7215069 | 0.86 | CA2 (0.38) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL13452860 | 0.86 | CA2 (0.41) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL1526766 | 0.86 | CA2 (0.41) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL5354914 | 0.84 | CA2 (0.37) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL5355528 | 0.84 | CA2 (0.37) | CA2CA1CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172321-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| US-7189706-B2 | C2,5′-disubstituted and N6,C2,5′-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | UNIVERSITEIT LEIDEN (NL) | 2007-03-13 | — | — | US | disclosed |
| US-7084127-B2 | C2,5′-disubstituted and N6, C2,5′-trisubstituted adenosine derivatives and their different uses | UNIVERSITEIT LEIDEN (NL) | 2006-08-01 | — | — | US | disclosed |
| EP-1121372-B1 | ADENINE DERIVATIVES | PFIZER LTD (GB) | 2006-06-28 | — | — | EP | disclosed |
| CN-1259332-C | C2,5'-disubstituted and N6, C2, 5' trisubstituted adenosine derivatives and their different uses | UNIV LEIDEN (NL) | 2006-06-14 | — | — | CN | disclosed |
| CN-1537115-A | C2,5'-disubstituted and N6, C2, 5' trisubstituted adenosine derivatives and their different uses | 莱顿大学 | 2004-10-13 | — | — | CN | disclosed |
| EP-1030856-B1 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-20040132686-A1 | C2,5'- disubstituted and N6, c2,5'- trisubstituted adenosine derivatives and their different uses | UNIVERSITEIT LEIDEN (NL) | 2004-07-08 | — | — | US | disclosed |
| US-20040127452-A1 | C2,5'-disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | UNIVERSITEIT LEIDEN (NL) | 2004-07-01 | — | — | US | disclosed |
| US-6740644-B2 | ADENOSINE DERIVATIVES, AGONISTS AT THE ADENOSINE A1 RECEPTOR | SMITHKLINE BEECHAM CORPORATION | 2004-05-25 | — | — | US | disclosed |
| US-6544960-B1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2003-04-08 | — | — | US | disclosed |
| EP-0901499-B1 | ADENOSINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2002-04-10 | — | — | EP | disclosed |
| US-6326359-B1 | PURINE DERIVATIVES | PFIZER INC | 2001-12-04 | — | — | US | disclosed |
| EP-1030856-A2 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999024451-A2 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 1999-05-20 | — | — | WO | disclosed |
| EP-0901499-A1 | ADENOSINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997043300-A1 | ADENOSINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1997-11-20 | — | — | WO | disclosed |
| WO-1997033590-A1 | A METHOD OF TREATING DISORDERS RELATED TO CYTOKINES IN MAMMALS | NOVO NORDISK A/S (DK) | 1997-09-18 | — | — | WO | disclosed |
| WO-1997033591-A1 | A METHOD OF TREATING DISORDERS RELATED TO CYTOKINES IN MAMMALS | NOVO NORDISK A/S (DK) | 1997-09-18 | — | — | WO | disclosed |
| US-5589467-A | TREATING CENTRAL NERVOUS SYSTEM DISORDERS | NOVO NORDISK A/S (DK) | 1996-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127452-A1 | C2,5'-disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | ADORA2A, ADORA3, ADORA1 | CA2 1681/4885CA1 4117/4885CA9 3524/4885 |
| US-20040132686-A1 | C2,5'- disubstituted and N6, c2,5'- trisubstituted adenosine derivatives and their different uses | ADORA2A, ADORA3, ADORA1 | CA2 2060/4885CA1 4122/4885CA9 3882/4885 |
| US-20120172321-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | CA2 4094/4885CA1 4587/4885CA9 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.